Risk factors of radiation-induced acute esophagitis in non-small cell lung cancer patients treated with concomitant chemoradiotherapy

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Zhang, ZiCheng ^a,b,c   Xu, Jin ^a,b   Zhou, Tao ^b   Yi, Yan ^b   Li, HongSheng ^b   Sun, HongFu ^b   Huang, Wei ^b   Wang, DongQing ^b   Li, BaoSheng ^a,b   Ying, GuoGuang ^a,c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

Acute esophagitis; Concomitant chemoradiotherapy; Non small cell lung cancer; Risk factors of acute esophagitis

Indexed keywords

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CISPLATIN; ESOPHAGITIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; RISK FACTORS; VINBLASTINE;

EID: 84894577907     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-54     Document Type: Article

References (20)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30. 10.3322/caac.21166, 23335087.
2. Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol 2008, 3:819-831. 10.1097/JTO.0b013e31818020eb, 18670299.
3. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L, . International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thor Oncol 2007, 2:706-714. International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions.
4. Robinson LA, Ruckdeschel JC, Wagner H, Stevens CW, . American College of Chest Physicians Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(Suppl 3):243S-265S. American College of Chest Physicians.
5. Socinski MA, Zhang C, Herndon JE, Dillman RO, Clamon G, Vokes E, Akerley W, Crawford J, Perry MC, Seagren SL, Green MR. Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol 2004, 15:1033-1041. 10.1093/annonc/mdh282, 15205196.
6. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 1995, 31:1341-1346. 10.1016/0360-3016(95)00060-C, 7713792.
7. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:2181-2190. 10.1200/JCO.2009.26.2543, 20351327.
8. Vokes EE, Herndon JE, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIb non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002, 20:4191-4198. 10.1200/JCO.2002.03.054, 12377962.
9. Squier CA, Kremer MJ. Biology of oral mucosa and esophagus. J Natl Cancer Inst Monogr 2001, 29:7-15.
10. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB, . Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004, 100(Suppl 9):1995-2025. Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology.
11. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST, . Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004, 100(Suppl 9):2026-2046. Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology.
12. Peterson DE, Bensadoun RJ, Roila F, . ESMO Guidelines Working Group Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines. Ann Oncol 2011, 22(Suppl 6):vi78-vi84. 3662500, 21908510, ESMO Guidelines Working Group.
13. Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 2006, 14:505-515. 10.1007/s00520-006-0055-4, 16601950.
14. Keefe DM, Gibson RJ, Hauer-Jensen M. Gastrointestinal mucositis. Semin Oncol Nurs 2004, 20:38-47. 10.1053/j.soncn.2003.10.007, 15038516.
15. Chen YM, Perng RP, Shih JF, Tsai CM, Whang-Peng J. A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan. Lung Cancer 2007, 56:363-369. 10.1016/j.lungcan.2007.01.011, 17306906.
16. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003, 21:3016-3024. 10.1200/JCO.2003.12.046, 12837811.
17. Werner-Wasik M, Yorke E, Deasy J, Nam J, Marks LB. Radiation dose-volume effects in the esophagus. Int J adiat Oncol Biol Phys 2010, 76(Suppl 3):S86-S93.
18. Kwint M, Uyterlinde W, Nijkamp J, Chen C, de Bois J, Sonke JJ, van den Heuvel M, Knegjens J, van Herk M, Belderbos J. Acute esophagus toxicity in lung cancer patients after intensity modulated radiation therapy and concurrent chemotherapy. Int J Radiat Oncol Biol Phys 2012, 84(2):e223-e228. 10.1016/j.ijrobp.2012.03.027, 22560551.
19. Algara M, Rodríguez N, Viñals P, Lacruz M, Foro P, Reig A, Quera J, Lozano J, Fernández-Velilla E, Membrive I, Dengra J, Sanz X. Prevention of radiochemotherapy-induced esophagitis with glutamine: results of a pilot study. Int J Radiat Oncol Biol Phys 2007, 69:342-349. 10.1016/j.ijrobp.2007.03.041, 17531398.
20. Rodríguez N, Algara M, Foro P, Lacruz M, Reig A, Membrive I, Lozano J, López JL, Quera J, Fernández-Velilla E, Sanz X. Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2009, 73:810-817. 10.1016/j.ijrobp.2008.04.064, 18755556.